chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. The reporter stated that up to 10 patients had received improperly stored vaccines during the time period of 17-SEP-2012 through 02-OCT-2012. Vaccines involved were M-M-R II, VAQTA, RECOMBIVAX HB and GARDASIL. No symptoms were reported. This is one of multiple reports from the same source (other case IDs 1210USA005704, 1210USA009229 and 1210USA009231). The follow-up information was received from the medical assistant refers to a the years old patient. The patient was vaccinated with improperly stored M-M-R II on 19-SEP-2012 (Intramuscularly in right thigh, lot# was reported as 0233AE, expiry date on 26-JAN-2014). Concomitant vaccines administered on the same day included varicella virus vaccine live (manufacturer unspecified) (lot # H007702, expiration: 30-MAR-2014, subcutaneously) in the right thigh, DAPTACEL (lot # C41S4BA, expiration: 06-OCT-2014, IM) in the left thigh, and poliovirus vaccine inactivated (manufacturer unspecified) (lot # H1330, expiration: 22-JUN-2014, subcutaneously) in the left thigh. The outcome of event was unknown. This is one of several reports received from the same reporter. The other patients' information was captured in 1210USA009230 and 1301USA001266 Additional information has been requested.
2.5 cm enlarged probable parotid glad no overlying erythema, not painful to touch, fluctuates in size during visit. no other s/s noted.   Dx ; Parotitis v lymphademopahy. no distress noted. playing and running around room .no fevers. labs were ordered but patient didn't have them drawn. (cbc, crp, esr-f ) ----- started Augmentin 600-42.9  mg/5ml for 10 days pt's mother stated improvement of area each day
On 11-30-2010 was noted pt received influenza #1- 11-2-10 and influenza #2- 11-12-10 mother aware.
Sever muscle aches, joint pain and headaches, along with some queasiness. The pain was debilitating. This start the evening of the booster dose and lasted for about 2 days. I just stayed home from work that Friday and took over the counter pain relief medicine, Tylenol. I was doing better by Sunday morning. this could have been  just a "fibro flare" brought on by the vaccine, but it was a bad one.
Patient presented to emergency department on 8/28/2021 with shortness of breath and cough. He admits to doing cocaine 2 days prior and smoking 5-6 cigarettes per day. He was found to COVID-19 positive at time of admission. He remained afebrile during admission and was treated for COPD exacerbation. He did not require any additional management due to COVID-19 infection. He was discharged home on 8/29/2021. Patient had previously tested positive for COVID-19 on 2/23/2021.
PATIENT SAID SHE HAD "HIVES AND FEVER WITH A FLU SHOT IN ABOUT 2013" BEFORE VACCINE. SHE SAID SHE HAD BENADRYL AND WOULD TAKE SOME AFTER THE SHOT TODAY. ABOUT 10 MIN AFTER VACCINATIION SHE COMPLAINED OF ITCY THROAT AND TOOK 25MG BENADRYL (IMMUNIZER WATCHED HER TAKE) AND DECLINED MORE BENADRYL AND EPINEPHRINE OFFERED BY IMMUNIZER. AT 1225PM SHE SAID SHE FELT BETTER AND LEFT. PATIENT DECLINED EPINEPHRINE AGAIN AND A RIDE OFFERED BY OTHER PERSON OR EMS. SAID SHE WAS GOING TO HER DAUGHTERS BECASUE SHE LIVED CLOSE AND HADNT EATEN ANY THING YET. SHE SAID SHE WAS GOING TO EAT, TAKE ANOTHER BENADRYL, AND RELAX. SAID SHE JUST "HAD ANXIETY". IMMUNIZER CALLED PATIENT AT 1235 TO ASK HOW SHE WAS DOING AND SHE SAID "BETTER, I'M ALMOST HOME." FOUND OUT AT 130P FROM PATIENT HUMAN RESOURCES REPRESENTATIVE THAT SHE WENT TO ED.
Wife called stating she took her husband to ER due to redness and pain at injection site.  She took him 6-19-16.
Redness at site, swelling at site, pain at site, headaches, warm to touch at site.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX (lot# and route unknown) to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2014, the physician administered the ZOSTAVAX vaccine to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. In 2016, the patient was treated by the physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
1335 Patient states her vision became blurry and she felt lightheaded and dizzy after vaccination. Patient assessed. Vitals T 97.3, P 80, O2 99%, BP 140/80, R 24. 1405 Vitals T 98%, P 86, O2 98%, BP 116/72, R 18. Patient states symptoms have subsided. Patient advised to contact primary provider and discharged.
This case was reported by a other health professional via call center representative and described the occurrence of injection site bruising in a female patient who received HAVRIX. Co-suspect products included BEXSERO, MENACTRA and PNEUMOVAX. On 1st April 2017, the patient received the 1st dose of HAVRIX. On 6th April 2017, the patient received BEXSERO. On 4th April 2017, the patient received MENACTRA vaccine. On 1st April 2017, the  patient received PNEUMOVAX. On 2nd April 2017, 1 days after receiving HAVRIX and not applicable after receiving BEXSERO, the patient experienced injection site bruising. On 9th April 2017, the patient experienced feeling hot. On an unknown date, the outcome of the injection site bruising and feeling hot were recovering/resolving.  It was unknown if the reporter considered the injection site bruising and feeling hot to be related to HAVRIX. It was unknown if the reporter considered the feeling hot to be related to BEXSERO. Additional details were reported as follows: The reporter was notified regarding the patient who was a new GSK employee. The patient received 1st dose of HAVRIX in left deltoid and experienced injection site bruising. On 9th April 2017, 3 days after receiving BEXSERO and 8 days after receiving HAVRIX, the patient felt feverish. It was unknown if the reporter considered the feeling hot to be related to MENACTRA and PNEUMOVAX as well. It was unknown if the reporter considered the injection site bruising to be related to MENACTRA as well. No other information was provided. Follow up was denied by the reporter.
Syncopal episode with walking away post-injection. Pt sent to Urgent Care for evaluation by doctor. He was monitored due to nausea and vomiting and released later that evening to home. He had multiple episodes of nausea and vomiting on the day he received the vaccine (after vaccination only)
Flu like symptoms from midnight following vaccine to midnight the next day. Fever (101 degrees F), chills, fatigue, muscle aches, sore throat
The patient was vaccinated at 09:12AM, and began experiencing tongue tingling and swelling on the right side after 20 minutes.  The patient reported that the tingling only lasted about a minute with the swelling occurring after.  Vital signs taken at 09:20AM.  The patient reported decrease in swelling at 10:18AM - "less swollen, more room."   Repeat vital signs at 10:20AM.  The patient reported resolution of symptoms and indicated that her tongue felt the same as it did prior to vaccination at 11:23AM.
This non-serious spontaneous case, initially received from other non-health professional on 14-Nov-2018, concerning a female patient of unspecified age. On an unspecified date, the FLUCELVAX QIVc vaccine underwent first temperature excursion with maximum temperature (Tmax) 8.2 degrees centigrade for 4 minutes. On 22-Oct-2018, vaccine underwent second temperature excursion with Tmax 9.8 degree centigrade for 23 minutes. On an unspecified date, two temperature excursions were identified after an audit. On 06-Nov-2018, the patient was inadvertently administered FLUCELVAX QIVc (dose: 0.5 ml, route of administration: intramuscular, anatomical location: right deltoid, batch number: 252672 and expiry date: 30-Jun-2019) which underwent temperature excursion. The patient did not experience any adverse effect after the vaccination.
Redness, swelling, hot to touch, very painful with in 24 hrs, worse in 48 hrs.
Giant flare up of lichen sclerosus and at 6 incision sites of elective surgery done 5 months previously (sept 2020).  Today it is reduced but still present.  photos available.
Received shot Tues PM at 1:30. Began having hot flashes and cold flashes which stopped around 5:30 after a couple of Bufferin Immediate Release, heart rate began. Took Blemeds around 6 PM. Had pt on same arm as injection that day. Fluid and redness around injection area. Started on antibiotics and redness is better.
rash around injection site the size of a 50 cent piece; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash around injection site the size of a 50 cent piece) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029A21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, the patient experienced VACCINATION SITE RASH (rash around injection site the size of a 50 cent piece). The patient was treated with PARACETAMOL (TYLENOL) for Vaccination site rash, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (rash around injection site the size of a 50 cent piece) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medication was reported.
Joint pain and inflammation around injection site.  The pain has spread throughout right arm from spine to fingertips.  Occassional Hot flash of fever on left side of body.
8 days after injection left deltoid (injection site) became swollen, red, and hot to touch.
Shingles; Red spots on patients eyelids and forehead; Severe headache lasting 8 days/ diagnosed as cluster headache; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles) and CLUSTER HEADACHE (Severe headache lasting 8 days/ diagnosed as cluster headache) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced CLUSTER HEADACHE (Severe headache lasting 8 days/ diagnosed as cluster headache). On 19-Mar-2021, the patient experienced HERPES ZOSTER (Shingles). On 19-Mar-2021, CLUSTER HEADACHE (Severe headache lasting 8 days/ diagnosed as cluster headache) had resolved. At the time of the report, HERPES ZOSTER (Shingles) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were provided.  No treatment information was provided.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: event outcome updated and reporter denied further follow up
Severe chills for 3 hours, eventually subsided after taking 2 Advil.
I started having tinnitus, I had it for 27 months. I went to my doctor and referred to so many doctors, I had so many MRI's done, I had a CT scan and I had a lot of stuff done. They still don't know what's going on and its severe. Super loud washing noise in my head for 24/7, that's the main thing and no one can figure out what's causing it.
patient complained because her leg hurt; 1st dose: 28-Jun-2022/2nd dose:19-Jul-2022; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN IN EXTREMITY (patient complained because her leg hurt) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose: 28-Jun-2022/2nd dose:19-Jul-2022) in a 3-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. AR9237B and AS1416B) for COVID-19 vaccination.     Patient did not have any allergies. Patient did not have any Acute and Chronic illnesses at the time of vaccination. Patient was not under any concomitant or regular medication.  The patient's past medical history included COVID-19 (she was hospitalized for 3 days and she was sick for almost 2 weeks) in August 2021.   On 28-Jun-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jul-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Jul-2022, the patient experienced PAIN IN EXTREMITY (patient complained because her leg hurt) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose: 28-Jun-2022/2nd dose:19-Jul-2022). On 21-Jul-2022, PAIN IN EXTREMITY (patient complained because her leg hurt) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose: 28-Jun-2022/2nd dose:19-Jul-2022) outcome was unknown.            No treatment medications were reported.   This case was linked to MOD-2022-661337, MOD-2022-661333 (Patient Link).
The patient developed a pruritic rash on bilateral arms about 2 hours after receiving the vaccine.  Advised to use BENADRYL. She will also Calamine lotion that she has at home. Advised to be seen if she develops any further symptoms such as tightening of the airway, shortness of breath, or symptoms worsen.
Report of patient hemorragic stroke with brain bleed, patient is reportedly in surgery at the moment.
Rash  red swollen at injection site, Severe headache and fever. Fever started the day after injection and lasted for two days. Fever ranged from 100 to 102. Fever finally broke on Saturday night but still have severe headache and arm is still red and swollen.
lt deltoid swollen & pink to touch 2 1/2" x 3 1/2"; t37.2, tingling in hand, fingers & wrist; rx cool compresses, advil prn; DPH for itching;
This spontaneous report was received from Employee, refers to a patient of unknown age and gender. No pertinent medical history reported. On an unknown date, approximately in September 2013 (a year ago) the patient received GARDASIL 1st dose (route, lot# were not reported) and on 12-SEP-2014, the patient received the 2nd dose of GARDASIL. Concomitant medications were unspecified by reporter. No adverse effects reported. No Product Quality Complaint (PQC) was involved. The reporter considered incorrect schedule to be not related to GARDASIL. The employee had attempted to conference the nurse, in order to report the adverse event however it was unsuccessful. Additional information has been requested.
No adverse event; Pediatric patient who was supposed to receive first dose received the second dose by mistake; This spontaneous case was reported by a consumer and describes the occurrence of CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Pediatric patient who was supposed to receive first dose received the second dose by mistake) and NO ADVERSE EVENT (No adverse event) in a 12-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010H22A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Oct-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Oct-2022, the patient experienced CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Pediatric patient who was supposed to receive first dose received the second dose by mistake). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Pediatric patient who was supposed to receive first dose received the second dose by mistake) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      Concomitant medications details were not reported by the reporter.  Reportedly, Patient was not sure if she had received an incorrect product of Moderna.  Treatment details were not reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 28-Oct-2022: Follow-up document contains updated start date of vaccine administration and narrative updated accordingly.
Double vision, pain, swelling, redness at injection site. Flu-liek symptoms, joint and muscular pain in whole muscular system ie, shoulders, arms ect. Autoimmune arhtritic symptoms. Follow-up report on 2/19/03: "Pain in arms and shoulders, sometimes pain whole muscular system. Suffer from arthritis like chronic inflammatory of joints, muscular system ocational shooting pain and burning sensation in extremities, i.e. hands and feet.  Annual follow up on 12/23/03: "Vaccine recipient has not recovered from the adverse events that was reported for this vaccination.  Auto immune arthritis like pain in muscle and arms, shoulders.  Flare-ups can last weeks.  Pain when lifting arms, very difficult to pull back my bow.  Need Celebrex to ease the pain, very delibitating.  Also shorting sharp burning pain in extremities, ie. fingers, hands feet etc.  Suffer from arthritis like chronic inflammation in joints and muscles.  Severe joint, muscle pain since vaccination in 2000."
Upon receiving Pfizer vaccine, patient was instructed to remain in store for any reactions. Patient began walking in the aisle of the store, then quickly approached pharmacy lobby area while holding back of head with dripping blood. He reported feeling dizzy and fainted. Pharmacy staff came to quickly aid with ice packs and water. Emergency personnel was contacted as well as patient's family members. Patient was closely monitored for consciousness and activity. Patient's father and girlfriend had arrive and was also monitoring patient. Emergency response was contacted a 2nd time for ETA arrival. Paramedics arrived on scene within 15 minutes and carefully assessed patient. After thorough assessment, patient decided to have his father transport him to urgent care. Paramedics and pharmacy staff safely escorted patient and family members off pharmacy premises. Patient was transported to urgent care with father.
Patient developed granuloma annulare on her left hand (one large lesion). Additional lesions appeared after completion of second dose on both arms and hands (3.25.21 Pfizer Lot# EN6208).
Arm soreness; Jan 21 to come in to get my first shot / Jan. 24 that I could come in to get my second shot; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On 24th January 2020, the patient received the 2nd dose of Shingrix. In January 2020, less than a week after receiving Shingrix, the patient experienced pain in arm. On 24th January 2020, the patient experienced drug dose administration interval too short. Rechallenge with Shingrix was positive. In January 2020, the outcome of the pain in arm was recovered/resolved. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were reported as follows: On 21st January 2020, patient received 1st dose of Shingrix in left arm. The patient received 2nd dose of Shingrix on right arm, before than the recommended interval, which led to shortening of vaccination schedule. She experienced arm soreness in each arm for a couple of days following the shots. The reporter consented to follow up.
per patient, 3 weeks after her shots, she developed shingles on the left side of her face and in her ear.  she felt it was going down her arm.  when she couldn't stand the pain any more, she went to urgent care.  The md speculated that the pharmacist had hit a tendon while administering the shot, but pt felt the shingles was going down her arm.  She has slowly lost the use of her left arm and is in constant pain.  Said she was unable to get in to see her md.  The urgent care md didn't do blood work, against pt request.  encouraged patient to seek care from her primary.
I started having numbness and tingling  in my left hand and also in the right hand. Went to a hand surgeon. I had a carpel tunnel surgery and symptoms are still there.
My left shoulder started pinching.  The pain progressed to point of doctor visit.  Am currently doing physical therapy for left shoulder.
pt came in after his covid vaccine stating he was feeling dizzy and light headed. I had him sit down and got some vitals on him BP 158/82 p-78 o2-96 I had him lay down for a while and gave him some water. after about 15 minutes I went back in the room and asked him how he was feeling. pt stated he was feeling a bit better than when he came in. I asked when the last time he ate anything, he stated he ate around 1pm. I got the lab to run BS and it came back at 132.  I had him sit up for another 10-15 minutes. I consulted AH and she told me to have him sit and keep observing him and also report to VAERS. after 15 minutes I went back in, pt stated he was still feeling better and i took his vitals again BP-146/78 p-63 o2-95. I told the pt to stay seated for a little while longer and he agreed. this time. pt stated that he does keep track of his BP and the readings we were getting seems to be  bit higher. i asked him if he was on BP medication and he stated that he was and he did take it today. He stayed seated for 5-10 more minutes and i took his BP 150/78 he stted that he felt better not 100% but well enough to get home. i advised if he didnt feel well he did not have to go, he stated he felt well enough. i advised pt to call the office if he had any further questions or concerns, i also advised to go to UC or ER if he started to feel dizzy and light headed again. pt verbalized understanding.